Craft

Samsung Biologics

Stock Price

₩788 K

2024-05-17

Market Capitalization

₩55.6 T

2024-05-14

Revenue

₩3.7 T

FY, 2023

Samsung Biologics Summary

Company Summary

Overview
Samsung Biologics (삼성바이오로직스) is a contract development and manufacturing organization. It provides cell line development, final aseptic fill, laboratory testing, process development, drug production, investigational new drug (IND) filing support, and other solutions to commercial manufacturers of drug substances and products. The company offers current good manufacturing practice (cGMP) facilities providing clinical and commercial products based on mammalian cell culture.
Type
Public
Status
Active
Founded
2011
HQ
Incheon, KR | view all locations
Website
https://www.samsungbiologics.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • John Rim

    John Rim, President & CEO, Chairman

  • Dongjoong Kim

    Dongjoong Kim, Executive Vice President & CFO

    • Namjin Chung

      Namjin Chung, Executive Vice President & CSO

    • Gail Ward

      Gail Ward, Executive Vice President & CQO

    Operating MetricsView all

    Global Customers

    100

    Feb, 2024

    Trademark Applications

    8

    Feb, 2024

    Trademarks

    25

    Feb, 2024

    LocationsView all

    4 locations detected

    • Incheon, Incheon HQ

      Korea (Republic of)

      300, Songdo bio-daero, Yeonsu-gu

    • Boston, MA

      United States

      260 Franklin St

    • Ridgefield Park, NJ

      United States

      100 Challenger Rd

    • South San Francisco, CA

      United States

      600 Gateway Blvd

    Samsung Biologics Financials

    Summary Financials

    Revenue (FY, 2023)
    ₩3.7T
    Gross profit (FY, 2023)
    ₩1.8T
    Net income (FY, 2023)
    ₩857.7B
    Cash (FY, 2023)
    ₩367.9B
    EBIT (FY, 2023)
    ₩1.1T
    Enterprise value
    $57.1T

    Footer menu